North America Startup Funding Rounds
Startups raising capital across North America. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 748 Jul 31 – Oct 28, 2026
- Disclosed funding
- $112B 595 disclosed amounts
- Median round
- $25M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| S SapienCompany profile Sapien builds an AI platform that connects financial results with the operational decisions behind them. Sapien builds an AI platform that connects financial results with the operational decisions behind them. | Undisclosed | Neo-led financingUndisclosed | Enterprise software | United States | Investors | |
| MB Moonwalk BiosciencesCompany profile Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. | $70M | Series B | Biotech | United States | Investors | |
| F Fab2Company profile Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. | $500M | Series A | Hardware | United States | Investors | |
| BB BrainChild BioCompany profile BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. | $116M | Series A | Biotech | United States | Investors Undisclosed | |
| TI Tokoshie, Inc.Company profile The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models. The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models. | Undisclosed | FundingUndisclosed | AI | United States | Investors | |
| P ParlayXCompany profile ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. | $1.3M | Pre-SeedPre-seed | Fintech | United States | Investors | |
Gimlet LabsCompany profile Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. | $300M | Series B | AI | United States | Investors | |
| CB Cloverleaf BioCompany profile Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. | $33M | Seed | Biotech | United States | Investors | |
| A AntiochCompany profile Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. | $32M | Series A | AI | United States | Investors | |
| E EmberosCompany profile Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms. Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms. | $5.5M | Seed | Enterprise software | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 31, 2026
- 1Y Combinator (YC)
Vera Health, BioStack, Tractian
56rounds3led - 2Andreessen Horowitz (a16z)
Hex, ASI, Eka Robotics
43rounds16led - 3Sequoia Capital
Hex, Warhound, Whop
25rounds7led - 4Khosla Ventures
Arda Industries, Tolan
25rounds6led - 5General Catalyst
Hyperbolic, Re:Build, Provision Labs
24rounds7led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.